May 24, 2018—Janssen Therapeutics, a Division of Janssen Products, LP (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will continue to provide SIRTURO® (bedaquiline) via its donation program with the United States Agency for International Development (USAID) and JSC Pharmstandard until early March 2019 to treat multidrug-resistant tuberculosis (MDR-TB) in currently eligible low- and middle-income countries.
Since the four-year Bedaquiline Donation Program was launched in April 2015, over 60 countries have accessed donated treatments. Due to high demand and patient need, all of the initially committed quantities (30,000 courses) are expected to be allocated to countries in the coming months.
Janssen has amended its agreement with USAID to meet patient need until early March 2019 by committing to donate up to 30,000 additional courses of bedaquiline. Eligible countries will be able to continue requesting bedaquiline—free of charge—through the usual channels, based on anticipated patient need in each country during this time.
This builds on Johnson & Johnson’s long-standing commitment to ensuring that bedaquiline is accessible to patients who need it. Later this year, the company will announce a new sustainable access program for the post-donation period. Johnson & Johnson and its partners are committed to providing adequate lead time and support to countries as needed ahead of any impending transitions.
For more information, please contact:
Ana-Maria Ionescu, aionescu@its.jnj.com